Drug repurposing—an emerging strategy in cancer therapeutics

Turabi, Khadija Shahab; Deshmukh, Ankita Jaywant; Paul, Sayan; Swami, Dayanand; Siddiqui, Shafina; Kumar, Urwashi; Naikar, Shreelekha; Devarajan, Shine; Basu, Soumya; Paul, Manash K.; Aich, Jyotirmoi

doi:10.1007/s00210-022-02263-x

Cited by 19 publications

(10 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In response, doctors are now using drugs developed for treating variola to treat monkeypox. The approach of drug repurposing provides cheap, effective and safe monkeypox drugs with few side effects and speeds up the monkeypox drug development process [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

The global patent landscape of emerging infectious disease monkeypox

Cai,

Zhang,

Zhang

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Background Monkeypox is an emerging infectious disease with confirmed cases and deaths in several parts of the world. In light of this crisis, this study aims to analyze the global knowledge pattern of monkeypox-related patents and explore current trends and future technical directions in the medical development of monkeypox to inform research and policy. Methods A comprehensive study of 1,791 monkeypox-related patents worldwide was conducted using the Derwent patent database by descriptive statistics, social network method and linear regression analysis. Results Since the 21st century, the number of monkeypox-related patents has increased rapidly, accompanied by increases in collaboration between commercial and academic patentees. Enterprises contributed the most in patent quantity, whereas the initial milestone patent was filed by academia. The core developments of technology related to the monkeypox include biological and chemical medicine. The innovations of vaccines and virus testing lack sufficient patent support in portfolios. Conclusions Monkeypox-related therapeutic innovation is geographically limited with strong international intellectual property right barriers though it has increased rapidly in recent years. The transparent licensing of patent knowledge is driven by the merger and acquisition model, and the venture capital, intellectual property and contract research organization model. Currently, the patent thicket phenomenon in the monkeypox field may slow the progress of efforts to combat monkeypox. Enterprises should pay more attention to the sharing of technical knowledge, make full use of drug repurposing strategies, and promote innovation of monkeypox-related technology in hotspots of antivirals (such as tecovirimat, cidofovir, brincidofovir), vaccines (JYNNEOS, ACAM2000), herbal medicine and gene therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

The global patent landscape of emerging infectious disease monkeypox

Cai,

Zhang,

Zhang

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…Therefore, there is a need to discover new medications to treat cancer. Drug repurposing is one of the cutting-edge strategies that focused on finding new indications for the already known clinically approved drugs 80 . Recent advancements in high-dimensional genomics, proteomics, and computational therapeutic approaches make DR an effective strategy for the treatment of cancer and other human diseases 81 , 82 .…”

Section: Discussionmentioning

confidence: 99%

Repurposing of neprilysin inhibitor ‘sacubitrilat’ as an anti-cancer drug by modulating epigenetic and apoptotic regulators

Kumbhar,

Nimal,

Patil

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Modifications in the epigenetic landscape have been considered a hallmark of cancer. Histone deacetylation is one of the crucial epigenetic modulations associated with the aggressive progression of various cancer subtypes. Herein, we have repurposed the neprilysin inhibitor sacubitrilat as a potent anticancer agent using in-silico protein–ligand interaction profiler (PLIP) analysis, molecular docking, and in vitro studies. The screening of PLIP profiles between vorinostat/panobinostat and HDACs/LTA4H followed by molecular docking resulted in five (Sacubitrilat, B65, BDS, BIR, and NPV) FDA-approved, experimental and investigational drugs. Sacubitrilat has demonstrated promising anticancer activity against colorectal cancer (SW-480) and triple-negative breast cancer (MDA-MB-231) cells, with IC50 values of 14.07 μg/mL and 23.02 μg/mL, respectively. FACS analysis revealed that sacubitrilat arrests the cell cycle at the G0/G1 phase and induces apoptotic-mediated cell death in SW-480 cells. In addition, sacubitrilat inhibited HDAC isoforms at the transcriptomic level by 0.7–0.9 fold and at the proteomic level by 0.5–0.6 fold as compared to the control. Sacubitrilat increased the protein expression of tumor-suppressor (p53) and pro-apoptotic makers (Bax and Bid) by 0.2–2.5 fold while decreasing the expression of anti-apoptotic Bcl2 and Nrf2 proteins by 0.2–0.5 fold with respect to control. The observed cleaved PARP product indicates that sacubitrilat induces apoptotic-mediated cell death. This study may pave the way to identify the anticancer potential of sacubitrilat and can be explored in human clinical trials.

show abstract

“…It is noteworthy that the utilization of novel drugs may incur exorbitant costs that exceed the financial capabilities of ordinary households [ 45 , 47 ]. Drug repurposing is an emerging strategy that involves identifying new therapeutic uses for approved or investigational drugs [ 48 , 49 ]. Compared to the traditional drug development process which is characterized by high costs, prolonged timelines, and high failure rates, drug repurposing offers several advantages.…”

Section: Discussionmentioning

confidence: 99%

High G9a Expression in DLBCL and Its Inhibition by Niclosamide to Induce Autophagy as a Therapeutic Approach

Hsu,

Chang,

Chuang

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Diffuse large B-cell lymphoma (DLBCL) is a malignant lymphoid tumor disease that is characterized by heterogeneity, but current treatment does not benefit all patients, which highlights the need to identify oncogenic genes and appropriate drugs. G9a is a histone methyltransferase that catalyzes histone H3 lysine 9 (H3K9) methylation to regulate gene function and expression in various cancers. Methods: TCGA and GTEx data were analyzed using the GEPIA2 platform. Cell viability under drug treatment was assessed using Alamar Blue reagent; the interaction between G9a and niclosamide was assessed using molecular docking analysis; mRNA and protein expression were quantified in DLBCL cell lines. Finally, G9a expression was quantified in 39 DLBCL patient samples. Results: The TCGA database analysis revealed higher G9a mRNA expression in DLBCL compared to normal tissues. Niclosamide inhibited DLBCL cell line proliferation in a time- and dose-dependent manner, reducing G9a expression and increasing p62, BECN1, and LC3 gene expression by autophagy pathway regulation. There was a correlation between G9a expression in DLBCL samples and clinical data, showing that advanced cancer stages exhibited a higher proportion of G9a-expressing cells. Conclusion: G9a overexpression is associated with tumor progression in DLBCL. Niclosamide effectively inhibits DLBCL growth by reducing G9a expression via the cellular autophagy pathway; therefore, G9a is a potential molecular target for the development of therapeutic strategies for DLBCL.

show abstract

Drug repurposing—an emerging strategy in cancer therapeutics

Cited by 19 publications

References 165 publications

The global patent landscape of emerging infectious disease monkeypox

The global patent landscape of emerging infectious disease monkeypox

Repurposing of neprilysin inhibitor ‘sacubitrilat’ as an anti-cancer drug by modulating epigenetic and apoptotic regulators

High G9a Expression in DLBCL and Its Inhibition by Niclosamide to Induce Autophagy as a Therapeutic Approach

Contact Info

Product

Resources

About